First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.

ABSTRACT

Background: The benefit of first-line use of sodium-dependent glucose transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus (T2DM) with low risk of cardiovascular diseases are not clear. Methods: PubMed, EMBASE and Cochrane Library databases were searched to identify eligible randomized controlled trials. We used the odds ratio (OR) and mean difference (MD) and the corresponding 95% confidence interval (CI) to assess the dichotomous and continuous variable, respectively. Results: Thirteen studies involving 2,885 T2DM at low risk of cardiovascular diseases were included. Compared to placebo, first line use of SGLT2i significantly reduced glycosylated hemoglobin type A1C (HbA1c) (MD -0.72), weight (MD -1.32) and fasting plasma glucose (FPG) (MD -27.05) levels. Compared with metformin, SGLT2i reduced body weight (MD -1.50) and FPG (MD -10.13) more effectively, with similar reduction for HbA1c (MD -0.05). No significant increased safety adverse was found for SGLT2i, including nasopharyngitis (OR 1.07), urinary tract infection (OR 2.31), diarrhea (OR 1.18) and hypoglycemia (OR 1.06). GLP-1RAs significantly reduced HbA1c (MD -1.13), weight (MD -2.12) and FPG (MD -31.44) levels as first-line therapy compared to placebo. GLP-1RAs significantly increased occurrence of diarrhea (OR 2.18), hypoglycemia (OR 3.10), vomiting (OR 8.22), and nausea (OR 4.41). Conclusion: First line use of SGLT2i and GLP-1RAs is effective in reducing HbA1c, weight, and FPG levels in T2DM patients at low risk for cardiovascular disease. SGLT2i may be superior to metformin in controlling body weight and FPG. GLP-1RAs may increase the occurrence of diarrhea, hypoglycemia, vomiting, and nausea. Systematic review registration PROSPERO (International Prospective Register of Systematic Reviews. https//www.york.ac.uk/inst/crd, CRD42022347233).